Regulus Therapeutics Inc. (NASDAQ:RGLS) shares saw an uptick in trading volume on Wednesday . 1,265,098 shares changed hands during trading, an increase of 47% from the previous session’s volume of 859,558 shares.The stock last traded at $3.94 and had previously closed at $3.52.

A number of brokerages have recently weighed in on RGLS. FBR & Co reaffirmed a “buy” rating and set a $30.00 target price on shares of Regulus Therapeutics in a research report on Sunday, April 17th. Needham & Company LLC reiterated a “buy” rating on shares of Regulus Therapeutics in a report on Tuesday, May 3rd. Cowen and Company reiterated a “buy” rating on shares of Regulus Therapeutics in a report on Monday, May 2nd. BMO Capital Markets reiterated a “buy” rating on shares of Regulus Therapeutics in a report on Monday, May 2nd. Finally, Wells Fargo & Co. began coverage on Regulus Therapeutics in a report on Tuesday, May 3rd. They set a “buy” rating for the company. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Regulus Therapeutics has a consensus rating of “Buy” and an average target price of $10.17.

The firm’s market capitalization is $216.40 million. The stock’s 50-day moving average price is $4.20 and its 200 day moving average price is $5.85.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Monday, May 2nd. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by $0.07. Analysts expect that Regulus Therapeutics Inc. will post ($1.54) earnings per share for the current fiscal year.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.